J 2025

Detection of early relapse in multiple myeloma patients

RŮŽIČKOVÁ, Tereza, Monika VLACHOVÁ, Lukáš PEČINKA, Monika BRYCHTOVÁ, Marek VEČEŘA et. al.

Basic information

Original name

Detection of early relapse in multiple myeloma patients

Authors

RŮŽIČKOVÁ, Tereza, Monika VLACHOVÁ, Lukáš PEČINKA, Monika BRYCHTOVÁ, Marek VEČEŘA, Lenka RADOVÁ, Simona ŠEVČÍKOVÁ, Marie JAROŠOVÁ, Josef HAVEL, Luděk POUR and Sabina ŠEVČÍKOVÁ

Edition

Cell Division, LONDON, BMC, 2025, 1747-1028

Other information

Language

English

Type of outcome

Article in a journal

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

is not subject to a state or trade secret

References:

Organization

Lékařská fakulta – Repository – Repository

UT WoS

001408777300001

EID Scopus

2-s2.0-85218041604

Keywords in English

Multiple myeloma; Liquid biopsy; Relapse microRNA; MALDI-TOF MS; Small RNA seq; Machine learning

Links

LX22NPO5102, research and development project. MUNI/A/1587/2023, interní kód Repo. NU21-03-00076, research and development project.
Changed: 15/3/2025 00:51, RNDr. Daniel Jakubík

Abstract

V originále

Background Multiple myeloma (MM) represents the second most common hematological malignancy characterized by the infiltration of the bone marrow by plasma cells that produce monoclonal immunoglobulin. While the quality and length of life of MM patients have significantly increased, MM remains a hard-to-treat disease; almost all patients relapse. As MM is highly heterogenous, patients relapse at different times. It is currently not possible to predict when relapse will occur; numerous studies investigating the dysregulation of non-coding RNA molecules in cancer suggest that microRNAs could be good markers of relapse. Results Using small RNA sequencing, we profiled microRNA expression in peripheral blood in three groups of MM patients who relapsed at different intervals. In total, 24 microRNAs were significantly dysregulated among analyzed subgroups. Independent validation by RT-qPCR confirmed changed levels of miR-598-3p in MM patients with different times to relapse. At the same time, differences in the mass spectra between groups were identified using matrix-assisted laser desorption/ionization time of flight mass spectrometry. All results were analyzed by machine learning. Conclusion Mass spectrometry coupled with machine learning shows potential as a reliable, rapid, and cost-effective preliminary screening technique to supplement current diagnostics.

Files attached